Use of Quantiferon-TB-Gold in Tube® test for detecting latent tuberculosis in patients considered as candidates for anti-TNF therapy in routine clinical practice


Department of Internal Medicine, Tuberculosis Unit, Hospital Son Llàtzer, Ctra de Manacor km 4, 07189 Palma de Mallorca, Islas Baleares, Spain
Microbiology Department, Hospital Son Llàtzer, Ctra de Manacor km 4, 07189 Palma de Mallorca, Islas Baleares, Spain
Rheumatology Department, Hospital Son Llàtzer, Ctra de Manacor km 4, 07189 Palma de Mallorca, Islas Baleares, Spain
Dermatology Department, Hospital Son Llàtzer, Ctra de Manacor km 4, 07189 Palma de Mallorca, Islas Baleares, Spain
Gastroenterology Department, Hospital Son Llàtzer, Ctra de Manacor km 4, 07189 Palma de Mallorca, Islas Baleares, Spain
Pneumology Department/Tuberculosis Unit, Hospital Son Llàtzer, Ctra de Manacor km 4, 07189 Palma de Mallorca, Islas Baleares, Spain

ARTICLE INFO
Article history:
Received 14 July 2011
Accepted 26 June 2012
Available online 16 August 2012

Keywords:
Latent tuberculosis infection
Anti-TNF treatment
Quantiferon-TB-Gold in Tube®
Tuberculin-skin test
Tuberculosis

ABSTRACT
Background/methods: Quantiferon-TB-Gold in Tube® test (QFT-G-IT) may have advantages if combined with TST when screening for Latent Tuberculosis Infection (LTBI) prior to initiating anti-TNF therapy in an area of intermediate tuberculosis incidence such as Spain. In a small-scale prospective study, we evaluate the use of QFT-G-IT in combination with the screening recommended in Spain (Tuberculin-Skin Test, TST retest, clinical data, and Chest X-Ray (CXR)) for LTBI in patients considered as candidates for anti-TNF therapy.

Results: From June 2008 to October 2010, 123 patients from a 300-bed hospital in Palma de Mallorca (Spain) were included in the study. The majority of patients were under immunosuppressive therapy. A positive TST and TST booster were found in 22 and 17 patients, respectively. Thus 39 (31.7%) of the 123 patients had a positive TST. QFT-G-IT was positive in 16 patients (13.6%), indeterminate in 4 (3.2%), and negative in 103 (83.7%). One of the two tests was positive in 42 patients (34.1%) of patients. The agreement between TST and QFT-G-IT among vaccinated patients was low and not statistically significant (Kappa = 0.15) and was almost perfect among non-BCG vaccinated patients (K = 0.81). TST positive responses were significantly related to BCG-vaccination (p < 0.05) and QFT-G-IT positive response rates were related to older age (p < 0.05).

Conclusion: QFT-G-IT may have advantages when combined with TST in immunosuppressed patients especially in older patients with a negative TST; in BCG vaccinated patients with a positive TST, QFT-G-IT could avoid unnecessary treatments and toxicities related to a false-positive TST result.

© 2011 Elsevier España, S.L. All rights reserved.
Introduction

The use of biological agents interfering with TNF α is an established tool in the treatment of an increasing number of immune-mediated inflammatory chronic diseases (IMIDs). However anti-TNFs cause immunosuppression and have been associated with the reactivation of latent tuberculosis infections (LTBI).1 The Food and Drug Administration2 and the European Medicines Agency3 recommend screening for LTBI prior to the use of anti-TNF agents. Patients with IMIDs are already at high risk of progression to active tuberculosis disease (TB) as a result of their treatments with glucocorticoids and other immunosuppressive therapies,4 and because of the inflammatory disease itself.5 Treatment with anti-TNF-α agents notably intensifies this threat.6 Spain, where the World Health Organization estimates the occurrence of 30 TB cases/100,000 population/year, is one of the Western European countries with the highest incidence of TB.7 An early report from the FDA in 2001 described 70 cases of TB associated with the reactivation of latent tuberculosis infections (LTBI).1 The Food and Drug Administration2 and the European Medicines Agency3 recommend screening for LTBI prior to the use of anti-TNF agents. Patients with IMIDs are already at high risk of progression to active tuberculosis disease (TB) as a result of their treatments with glucocorticoids and other immunosuppressive therapies,4 and because of the inflammatory disease itself.5 Treatment with anti-TNF-α agents notably intensifies this threat.6 Spain, where the World Health Organization estimates the occurrence of 30 TB cases/100,000 population/year, is one of the Western European countries with the highest incidence of TB.7 An early report from the FDA in 2001 described 70 cases of TB associated with the reactivation of latent tuberculosis infections (LTBI).1 The Food and Drug Administration2 and the European Medicines Agency3 recommend screening for LTBI prior to the use of anti-TNF agents. Patients with IMIDs are already at high risk of progression to active tuberculosis disease (TB) as a result of their treatments with glucocorticoids and other immunosuppressive therapies,4 and because of the inflammatory disease itself.5 Treatment with anti-TNF-α agents notably intensifies this threat.6

Interferon-γ Release Assays (IGRAs) have been introduced as important diagnostic tests, complementing or replacing the Tuberculin Skin-Test (TST) for the diagnosis of LTBI. Two ex vivo assay formats, ELISA and ELISpot, are used to detect the interferon-gamma (IFN-γ) response to specific-Mycobacterium tuberculosis (MTB) secreted proteins such as ESAT6, CFP-10, and TB7.7 (this additional antigen is only present in the last generation ELISA test). Both formats have commercially available tests: Quantiferon-TB-Gold in Tube® (QFT-G-IT)® (Cellestis Ltd., Carnegie, Australia) and T-SPOT.TB® (Oxford Immunotec, UK).9 Both have shown a higher specificity compared with TST especially in BCG-vaccinated populations and a higher sensitivity in immunodepressed patients, and positive IGRA responses are closely associated with risk factors for MTB infection.10 In some countries, IGRAs are already recommended for clinical use in immunodepressed patients who are candidates for anti-TNF α treatment.11,12 In Spain, guidelines recommend their use in clinical studies, always in combination with TST.13,14 For patients undergoing immunosuppressive treatment and considered as candidates for anti-TNFα treatment, the recommendations of the Spanish Health Authorities regarding LTBI screening include: obtaining a history of previous exposure, performing a positive initial TST or positive retest (booster), or a CXR finding suggestive of old TB. There are no specific recommendations regarding IGRAs in this setting.15–17

The aim of this study was to evaluate the usefulness of QFT-G-IT in combination with TST, booster TST, and CXR for the diagnosis of LTBI in patients considered as candidates for anti-TNFα treatment for different IMIDs in routine clinical practice in a hospital in Palma de Mallorca from 2008 to 2010.
tubes were incubated at 37 °C in a carbon dioxide incubator for 16–24 h. After overnight incubation, 200 μl plasma was removed from each tube and the IFN-γ concentration was measured using the assay kit according to manufacturer’s instructions. A positive result was defined as an IFN-γ concentration ≥0.35 IU/ml.

Results

One hundred and twenty-three patients were recruited and all consented to the study. There were two withdrawals during follow-up, both due to unexpected deaths which were unrelated to any infectious disease.

Median age was 45 years [range 18–79 years]. There were 105 (84.7%) patients born in Spain, 9 (7.32%) patients born in Western Europe, and 9 patients born in high TB-incidence countries (8 South America, 1 India). There were no patients with known HIV infection. Seventeen patients had at least one comorbidity considered as risk factor for TB disease: 4 (3.3%) had leukopenia, 4 (3.3%) had chronic renal disease, 9 (7.3%) had diabetes and 1 (0.8%) had chronic liver disease. There were neither intravenous drug abusers nor heavy alcohol consumers. Underlying IMIDs and BCG vaccination status are described in Table 1. The majority of patients (92.7%) were non-heavy alcohol consumers. Underlying IMIDs and BCG vaccination status were considered as risk factor for TB disease: 4 (3.3%) had leukopenia, 4 (3.3%) had chronic renal disease, 9 (7.3%) had diabetes and 1 (0.8%) had ankylosing spondylitis.

Of the 17 patients with comorbid conditions, 8 (47.1%) were among the 123 patients had a positive TST, 22 patients, and the TST-booster was positive in 16 patients (13.6%), indeterminate in 4 (3.2%), and negative in 103 (83.7%). One of the two tests was positive and LTBI was diagnosed in 42/123 (34.1%) patients. LTBI was diagnosed only through QFT-G-IT in 34/123 (2.4%) patients. Agreement among both tests was fair, either when the first TST (Kappa (K) = 0.31; CI 95%; 0.009–0.53; p < 0.05) or TST and TST retest were considered (K = 0.35; CI 95%; 0.18–0.52, p < 0.05) (Table 2).

The patients who had an indeterminate QFT-G-IT result had a negative TST.

In the bivariate analysis, QFT-G-IT positive response rates were related to older age [QFT-G-IT positive: mean age: 54.81 (SD: 12.97); QFT-G-IT negative: mean age: 45.22 (SD: 14.39); p < 0.05, CI 95%: 2.0–17.2]. This relationship with age was not observed for the TST (Fig. 1). Patients above 55 years old were at a higher risk for a QF-G-IT positive test than patients with 55 years old or younger (OR: 4.2, CI 95%: 1.5–12.2, p < 0.005). The multivariate analysis did not improve the bivariate analysis.

Among the 17 patients with comorbid conditions, 8 (47.1%) were diagnosed of LTBI, TST was positive in 8 (47.1%) cases, and QFT-G-IT was positive in 2 (11.8%) cases. We could not find any relationship between comorbidities and a negative TST or QFT-G-IT.

A positive TST was found in 22 patients, and the TST-booster was positive in 17 patients who previously had a negative TST. Thus 39 (31.7%) of the 123 patients had a positive TST. QFT-G-IT was positive in 16 patients (13.6%), indeterminate in 4 (3.2%), and negative in 103 (83.7%). The majority of patients (92.7%) were under immunosuppressive therapy (Table 1). One patient had a prior history of treated LTBI. Residual TB findings were described in CXR in 7 cases (5.9%).

**Table 1**

<table>
<thead>
<tr>
<th>Underlying IMID</th>
<th>Frequency, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Crohn’s disease</td>
<td>27 (22)</td>
</tr>
<tr>
<td>Ulcerative Colitis</td>
<td>12 (9.8)</td>
</tr>
<tr>
<td>Rheumatoid Arthritis</td>
<td>29 (23.6)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>18 (14.6)</td>
</tr>
<tr>
<td>Psoriatic Arthritis</td>
<td>13 (10.6)</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>15 (12.2)</td>
</tr>
<tr>
<td>Othersa</td>
<td>9 (7.2)</td>
</tr>
<tr>
<td>Total</td>
<td>123 (100)</td>
</tr>
</tbody>
</table>

a IMIDs include: uveitis (2 cases) and keratoderma, scleroderma, pemphigus, Behcet’s syndrome, Lupus Erythematosus, other vasculitis, epidermolysis acquisita, one case each.

**Table 2**

<table>
<thead>
<tr>
<th>Sex female/male</th>
<th>Frequency, n (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>62 (50.4)</td>
<td>61 (49.6)</td>
</tr>
<tr>
<td>BCG vaccination status</td>
<td></td>
</tr>
<tr>
<td>BCG vaccinated</td>
<td>23 (18.7)</td>
</tr>
<tr>
<td>Not BCG vaccinated</td>
<td>45 (36.6)</td>
</tr>
<tr>
<td>Unknown vaccination</td>
<td>55 (44.7)</td>
</tr>
<tr>
<td>Underlying IMID</td>
<td></td>
</tr>
<tr>
<td>Crohn’s disease</td>
<td>27 (22)</td>
</tr>
<tr>
<td>Ulcerative Colitis</td>
<td>12 (9.8)</td>
</tr>
<tr>
<td>Rheumatoid Arthritis</td>
<td>29 (23.6)</td>
</tr>
<tr>
<td>Psoriasis</td>
<td>18 (14.6)</td>
</tr>
<tr>
<td>Psoriatic Arthritis</td>
<td>13 (10.6)</td>
</tr>
<tr>
<td>Ankylosing spondylitis</td>
<td>15 (12.2)</td>
</tr>
<tr>
<td>Othersa</td>
<td>9 (7.2)</td>
</tr>
<tr>
<td>Total</td>
<td>123 (100)</td>
</tr>
</tbody>
</table>

a IMIDs include: uveitis (2 cases) and keratoderma, scleroderma, pemphigus, Behcet’s syndrome, Lupus Erythematosus, other vasculitis, epidermolysis acquisita, one case each.

**Fig. 1.** Percentages of BCG-vaccination and frequency of positive TST and positive QFT-G-IT (%) according to age group (in years) among the 123 patients.
None of the immunosuppressive treatments could be related to a negative TST or negative QFT-G-IT. Five patients had already received anti-TNF therapy when they were included in the study, all of them but one had negative TST and QFT-G-IT tests; a patient with both TST positive and QFT-G-IT positive tests was under anti-TNF therapy and had previously been diagnosed and treated for LTBI in another hospital. Four patients had an indeterminate QFT-G-IT result, two of them were receiving DMARDs whereas one was on anti-TNFx therapy; CXR was normal in all cases.

**Effect of BCG vaccination on TST and QFT-G-IT results**

Twenty-three patients had received previous BCG vaccination. The agreement between TST and QFT-G-IT among vaccinated patients was low and was not statistically significant, neither when considering only the first TST, $K = 0.18$ (CI 95%: -0.23 to 0.37, $p > 0.05$) nor when considering both, $K = 0.15$ (CI 95%: -0.30 to 0.32, $p > 0.05$) (Table 2). TST positive responses were significantly related to BCG-vaccination ($p < 0.05$) and this relationship was not observed for the QFT-G-IT.

BCG-vaccination status significantly affects the relationship between TST and QFT-G-IT (Mantel–Haenszel test, $p < 0.05$).

**Correlation between abnormal CXR and QFT-G-IT**

Seven patients had a CXR suggestive of past TB. 3 had a positive TST, and 2 had a positive QFT-G-IT. The two patients with a positive QFT-G-IT had negative TST and booster TST. Three sputum samples were collected from each of these patients for Acid-Fast Bacilli examination and for mycobacterium culture, and all were negative. When available, a previous CXR was evaluated by a radiologist to ensure the stability of the radiological findings.

**Treatment and follow-up**

All patients with either a positive QFT-G-IT or a positive TST were advised to receive treatment; 39/42 patients received 9-month isoniazid therapy and the treatment was changed to 4-month rifampicin therapy in 4 patients because of toxicity. One patient had already been treated for LTBI and two patients rejected treatment but they were not treated with anti-TNF therapy. In addition, two patients with an abnormal CXR and negative TST and QFT-G-IT had not started receiving anti-TNFx therapy yet and had not received LTBI treatment either. The median follow-up period was 31 months [range 1–47]. Fifty-two (42.3%) patients had already initiated an anti-TNFx therapy whereas 71 (57.7%) had not. TB was not reactivated in any of these cases during follow-up.

**Discussion**

In the current study, LTBI was diagnosed in 34.1% of patients considered as candidates for anti-TNFx treatment. This rate is higher than previously reported in studies conducted in Southern Europe which have found rates ranging from 12 to 22%.17,20 TST positive rates were higher among BCG-vaccinated patients than in non-BCG-vaccinated patients and this difference with regard to BCG vaccination was not seen in QFT-G-IT results. Furthermore, QFT-G-IT positive response rates were related to older age. In 3.2% of patients, LTBI was diagnosed only through QFT-G-IT.

This high prevalence of LTBI may be explained in various ways. First, in our study, a higher proportion of positive QFT-G-IT tests were detected in older patients. Patients over 65 years old were most likely exposed to MTB infection at a young age, when Spain was a very high incidence TB country in the 1950s and had a tuberculosis-related mortality above 125 deaths/100,000 persons/year.21 Therefore age is also a predictor of LTBI. We observed discordant results (negative TST/positive QFT-G-IT) among older patients. Our findings may be related to decreased immunity due to age resulting from a reduced mobility of the T lymphocytes that have to migrate to the forearm where the TST is applied, as has been previously described.22,23 The hypothesis that TST might be more sensitive to remote infections while IGRA mainly detects recent infections is not supported by our data.24 In addition, the higher rates of positive TSTs observed in the 31–55-year-old group could be related to BCG-vaccination. Despite a high proportion of patients with an unknown vaccination status, we have found that TST positivity is influenced by BCG-vaccination. It is generally agreed that BCG vaccination interferes with TST25,26 and 25% of individuals vaccinated at primary school may have persistent tuberculin reactions.25 The two-step TST may cause a booster phenomenon mostly related to the BCG-vaccine27 but in our study only 1/15 BCG-vaccinated patients were with a positive TST. This result could be related to the booster phenomenon. False positive results in TST induced by previous non-tuberculous mycobacteria sensitisation could be another possibility to be considered.28

In high and low TB incidence countries, a lower TST sensitivity has been demonstrated in immunosuppressed patients compared with immunocompetent patients.29,30 In our study, 4/123 (3.2%)
patients had discordant negative TST/positive QFT-G-IT results but an association with immunosuppressive therapy could not be demonstrated. Similar data have been described by other investigators, and only one study conducted in Peru in patients with rheumatoid arthritis has found a higher rate (23.8%) of discordant TST/positive QFT-G-IT. A small Spanish study in patients with inflammatory rheumatologic diseases found that positive TST, T-SPOT, TB and QFN-G-IT results were not affected by the immunosuppressive therapies. In our study, the rate of indeterminate results was low (3.4%), as previously described and we did not find any association between steroids or other immunosuppressive treatment and indeterminate results, as it has been suggested.

We have observed a good agreement between TST and QFT-G-IT in non-vaccinated patients and a poor agreement in vaccinated patients. BCG-vaccination status significantly affects the relationship between TST and QFT-G-IT. Studies in Italy and Turkey have found a similar rate of positive QFT-G-IT in immunosuppressed patients. In countries with a high BCG-vaccination rate, the percentage of discordant results (positive TST/negative IGRA) varies from 25.4% in a low TB incidence country such as Switzerland to 47.5% in a high TB incidence country such as Turkey. In two studies conducted in Germany and Italy, which have a low percentage of BCG-vaccinated patients, the proportion of discordant results (positive TST/negative flow-cytometric-interferon-γ assay or IGRA test) was low (7.2% and 6%, respectively). However, a recently published Spanish study found discordant positive TST/negative QFT-G-IT results in 8.5% but the authors were unable to demonstrate an association between these discordant results and BCG vaccination.

Clinical guidelines differ between countries. In Switzerland and the UK, TST is not recommended in patients under immunosuppressive treatment, and LTBI treatment is recommended if an IGRA test is positive or if there are risk factors for TB infection. In Germany, TST is recommended only if the IGRA test is negative and if there is any evidence of prior TB exposure. In France, TST is recommended for all patients and there is no guidance regarding the IGRA test. Spanish guidelines recommend an IGRA test for LTBI in controlled studies in immunodepressed patients with a negative TST and in BCG-vaccinated patients with a positive TST, but no specific recommendation about IGRA is made for patients on anti-TNF therapies.

Our study was decided to treat all patients with either a positive TST or a positive QFT-G-IT. There were patients with a probable false positive TST related to BCG vaccination, who had received unnecessary preventive TB treatment but most of the available information about IGRA in patients with IMID comes from small studies and false-negative results are not uncommon. We still do not have national recommendations about the use of IGRA in patients with IMID based on large-prospective randomized and controlled studies.

Our study is a small-scale pilot study and therefore shows some limitations. Underlying immune-mediated diseases and immunosuppressive treatments were heterogeneous, some patients had already been treated with anti-TNFα agents, and BCG-vaccination status could not be assessed in all patients, but this situation reflects what happens in the daily clinical practice. Furthermore, another limitation is the lack of a gold-standard method for the diagnosis of LTBI. Despite these limitations, our results suggest that QFT-G-IT may have advantages compared to TST when screening for LTBI before initiating anti-TNFα therapy in our setting, especially in old age and in BCG-vaccinated patients. In our opinion, QFT-G-IT should be used in immunosuppressed patients if the TST is negative and probably in BCG vaccinated patients with a positive TST to avoid unnecessary treatments and toxicities related to false-positive TST result. Large longitudinal studies are required in this setting to define the role of IGRA testing in the diagnosis of LTBI in patients considered as candidates for anti-TNFα therapy.

**Funding**

The study was supported by a grant from the Ministerio de Sanidad y Consumo Instituto de Salud Carlos III, Madrid, Spain, FIS 06/081.

**Conflict of interest**

The authors declare that they have no conflict of interest.

**Acknowledgements**

We would like to thank Claire Graham for translation assistance and Dr. Antonio Pareja for statistical assistance.

**References**

7. WHO Online Tuberculosis Database. http://apps.who.int/globalatlas/ [accessed 08.05.12].


